Novartis Ag (NVSEF) Operating Expenses (2009 - 2025)

Novartis Ag has disclosed Operating Expenses across 15 years of filings, most recently posting -$6.2 billion for Q2 2025.

• Operating Expenses for Q2 2025 came in at -$6.2 billion, down 13.03% year-over-year; the trailing twelve-month figure through Mar 2026 was -$6.2 billion (up 61.87% YoY), and the FY2025 annual result was $24.4 billion, up 8.23% from the prior year.
• Operating Expenses came in at -$6.2 billion for Q2 2025 at Novartis Ag, up from -$10.7 billion in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of -$672.0 million in Q3 2022 to a low of -$10.9 billion in Q4 2023.
• The 5-year median for Operating Expenses is -$3.1 billion (2021), against an average of -$4.0 billion.
• Peak annual rise in Operating Expenses reached 11.25% in 2023, while the deepest fall reached 1273.07% in 2023.
• Novartis Ag's Operating Expenses stood at -$808.0 million in 2021, then advanced by 2.1% to -$791.0 million in 2022, then slumped by 1273.07% to -$10.9 billion in 2023, then rose by 1.31% to -$10.7 billion in 2024, then soared by 42.45% to -$6.2 billion in 2025.
• The last three Operating Expenses figures came in at -$6.2 billion (Q2 2025), -$10.7 billion (Q4 2024), and -$5.5 billion (Q2 2024), per Business Quant data.